Respiratory syncytial virus (RSV) is a leading cause of lower respiratory infections in infants and the immunocompromised, yet no efficient therapeutic exists. We have identified the AVG class of allosteric inhibitors of RSV RNA synthesis.

Although human respiratory syncytial virus (RSV) is an important cause of illness and death in older adults, no RSV vaccine has been licensed.

We investigated duration of protection afforded by natural infection, the effect of viral immune evasion on duration of protection, and protection against severe reinfection, in Qatar, between February 28, 2020 and June 5, 2022.

A trio of new studies from the United States and Europe explore a possible link between COVID-19 and new-onset type 1 diabetes (T1D) in children.

Global influenza circulation has been heavily suppressed by public health measures and travel restrictions since the onset of the COVID-19 pandemic.

These new subvariants carrying further mutations in their spike proteins raise concerns that they may further evade neutralizing antibodies.

An infectious etiology of Alzheimer’s disease has been postulated for decades. It remains unknown whether SARS-CoV-2 viral infection is associated with increased risk for Alzheimer’s disease.

Nivel is researching the impact of COVID-19 on Influenza activity combining data from around the world.

Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years).

Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years).

All presentations of the 2022 ESWI Respiratory virus Summit are available to watch on vimeo.

The role of immune responses to previously seen endemic coronavirus epitopes in severe acute respiratory coronavirus 2 (SARS-CoV-2) infection and disease progression has not yet been determined.